Tazemetostat for Follicular Lymphoma

"According to the listing on clinicaltrials.gov, this study is not presently looking for patients as recruitment has closed. The trial was initially posted on December 15th, 2022 and last updated on October 26th, 2022. Even though this particular trial is not ongoing, there are 1796 other trials that are currently recruiting patients."

"Unfortunately, this study is not currently recruiting patients. The listing was first created on December 15th, 2022 and edited most recently on October 26th, 2022. However, there are 35 other trials for Tazemetostat that are looking for participants right now, as well as 1761 studies concerning lymphoma, follicular."

"Tazemetostat is a medication used to target b-lymphocytes, but can also be useful in the treatment of other conditions like lymphoma and follicular lymphoma."

"Tazemetostat has undergone extensive clinical testing with 35 active studies and 5 trials in Phase 3. The majority of these medical trials are based out of San Antonio, Texas; however, there are 1,627 total locations where Tazemetostat is being studied."

"Tazemetostat has been researched since 2014 when the first study, sponsored by TG Therapeutics, Inc., was conducted with 45 participants. After Phase 1 approval was received in 2014, there are now 35 active studies involving Tazemetostat being conducted in 581 different cities across 27 countries."

"The aim of this study is to establish the maximum tolerated dose of the medication. To do this, researchers will follow patients for up to 2 years and track any reports of toxicity. Additionally, they will also measure secondary outcomes like complete response rate (defined as the proportion of patients who achieve a complete or partial response), overall survival rate (estimated using the Kaplan-Meier method), and time to response."